Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.

Kyunghye BangJaekyung CheonJae Ho JeongHyeon-Su ImKyu-Pyo KimBaek-Yeol RyooChanghoon Yoo

Published in: Therapeutic advances in medical oncology (2021)

Nal-IRI plus 5-FU/LV showed modest effectiveness and manageable toxicities for patients with mPAC previously treated with conventional irinotecan-containing chemotherapy. The cumulative dose of prior conventional irinotecan therapy may be inversely correlated with the effectiveness of nal-IRI plus 5-FU/LV.

Keyphrases

newly diagnosed
randomized controlled trial
end stage renal disease
systematic review
squamous cell carcinoma
ejection fraction
chronic kidney disease
locally advanced
prognostic factors
patient reported outcomes
bone marrow
patient reported